Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

Annals of Oncology : Official Journal of the European Society for Medical Oncology
G FountzilasM A Dimopoulos

Abstract

To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy. From January 1999 to April 2002, 327 eligible patients with ABC were randomized to receive either paclitaxel 175 mg/m(2) in a 3-h infusion followed by epirubicin (EPI) 80 mg/m(2) (group A) or paclitaxel, as in group A, followed by Cp at an AUC of 6 mg x min/ml (group B) every 3 weeks for six cycles. After a median follow-up of 23.5 months, median survival was not significantly different between the two groups (22.4 months versus 27.8 months, P=0.25), whereas median time to treatment failure was significantly longer in patients treated with paclitaxel/Cp (8.1 months in group A versus 10.8 months in group B, P=0.04). Both regimens were well tolerated. In total, 39 patients (24%) in group A and 46 (29%) in group B suffered at least one severe side-effect. Quality-of-life assessment and cost analysis did not reveal any significant differences between the two groups. Our study suggests that the paclitaxel/Cp combination is an effective therapeutic alternative for patients with ABC in which anthracycline administration has the potential of being harmful.

References

Oct 1, 1973·Annals of Internal Medicine·R W Jelliffe
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G FountzilasD Skarlos
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G FountzilasD Skarlos
Feb 3, 2000·Journal of the National Cancer Institute·E A Gehan, M C Tefft
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SjöströmC Blomqvist
Mar 20, 2002·Clinical Breast Cancer·M Martín
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S FogliM Del Tacca
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Marc NabholtzUNKNOWN TAX 306 Study Group

❮ Previous
Next ❯

Citations

May 4, 2005·Cancer Chemotherapy and Pharmacology·G P StathopoulosJ Xynotroulas
Dec 9, 2010·Cancer Chemotherapy and Pharmacology·Elisabeth I HeathGeorge Wilding
Jan 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Orit FreedmanMark Clemons
Oct 26, 2005·International Journal of Clinical Oncology·Takehiko SegawaOsamu Ogawa
Nov 17, 2009·Breast Cancer Research and Treatment·U DafniG Fountzilas
Sep 3, 2010·Nature Reviews. Clinical Oncology·Carlo PalmieriDavid Miles
Mar 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X S ChenK W Shen
Dec 11, 2008·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Jan 11, 2011·Journal of the National Cancer Institute·Julie LemieuxValérie Théberge
Feb 14, 2009·Current Medical Research and Opinion·Nikos ManiadakisGeorge Fountzilas
Aug 19, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Tulay KusCelaletdin Camci
Aug 3, 2011·Cancer Treatment Reviews·Krzysztof AdamowiczEverardo D Saad
Aug 30, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicholas Wilcken, Rachel Dear
Jun 8, 2012·European Journal of Cancer Care·E ReedJ Hawthorn
Mar 11, 2008·Critical Reviews in Oncology/hematology·Andreas A ArgyriouHaralabos P Kalofonos
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John HornbergerStephen Raab
Jan 18, 2012·Chemotherapy·Ali I Shamseddine, Fadi S Farhat
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda E KielyMartin R Stockler
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J Lee, Sandra M Swain
May 16, 2014·World Journal of Clinical Oncology·Budhi Singh YadavSwaty Jhamb
Oct 21, 2004·The Cochrane Database of Systematic Reviews·S LordJ Simes
Dec 7, 2007·The Oncologist·Alessandro MorabitoUNKNOWN NCI Naples Breast Cancer Group
Oct 13, 2004·The Oncologist·Edith A Perez
Nov 3, 2016·Breast Cancer Research and Treatment·Fausto PetrelliSerena Di Cosimo
Feb 7, 2019·Case Reports in Oncological Medicine·Néstor Llinás-QuinteroLuis J Gallón-Villegas
Jun 24, 2017·The Cochrane Database of Systematic Reviews·Sam J EggerNicholas Wilcken
Oct 22, 2020·The Cochrane Database of Systematic Reviews·Sam J EggerNicholas Wilcken
Apr 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·William J GradisharRashmi Kumar
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yumiko ShimanukiChikako Shimizu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved